This year, New Jersey voters will be presented with a referendum on whether to legalize cannabis for adult use.  Join Fox for an interactive discussion featuring insider perspectives on the potential impact of both possible outcomes.  Click the link here to register for free.

Topics will include: 1) Overview of New Jersey’s regulatory environment; 2) The current state of the medical-use market; 3) Business opportunities and challenges in the potential new adult-use market, and 4) New Jersey’s importance to the cannabis industry.

Moderator:

  • Elizabeth Litten, Partner, Fox Rothschild LLP

Speakers:

  • Assemblyman Gary Schaer, Deputy Speaker, New Jersey Legislature
  • Peter Kelly, Partner, Fox Rothschild LLP
  • Jason Morris, Senior VP, Operations, TerrAscend NJ
  • Dina Rollman, Senior VP, Government & Regulatory Affairs, Green Thumb Industries
  • Jeremy Unruh, Senior VP, Public & Regulatory Affairs, PharmaCann

See you there!

 

On August 25th, Pennsylvania’s Governor Tom Wolf called for the legalization of recreational cannabis to assist with the state’s efforts in supporting small businesses that have been negatively impacted by COVID-19.

Pennsylvania’s small businesses and hospitality sectors have been hit hard by COVID-19 and the State has incurred steep costs in an effort to help those struggling businesses.  Gov. Wolf’s proposal to legalize recreational cannabis would generate additional tax revenue for the state and assist with the COVID-19 support.  In addition to generating additional funds to support small businesses, half of the tax revenue generated by recreational cannabis sales would be directed to historically disadvantaged businesses.

For additional information on Gov. Wolf’s proposal, check out this article by the Philidelphia Business Journal: Wolf calls for recreational marijuana to be legalized to help with Covid relief funding.

Most states have seen an increase in their costs due to COVID-19.  Whether it is an increase in unemployment or additional assistance offered to businesses, states across the board have seen an increase in expenditures.  Cannabis legalization can play a pivotal role in helping states meet their new burdens and challenges.  Gov. Wolf may be one of many government officials that will begin pushing their states to legalize cannabis sales as they take notice of the tax revenues generated by the states that have legalized cannabis before the pandemic.  Currently, Pennsylvania only allows medicinal cannabis sales.  If it agrees with Gov. Wolf’s proposal, it will join 11 other states that have legalized recreational cannabis in the U.S.

In Illinois, many new craft grower, infuser and transporter licenses were supposed to be issued by the Department of Agriculture on July 1, 2020. But, because of COVID-19, the issuance of those licenses has been delayed until possibly September 2020. The exact date remains uncertain.

Many potential applicants intended to qualify as a Social Equity Applicant by hiring a certain number of qualifying employees. One way to qualify as a Social Equity Applicant in Illinois is to hire a minimum of 10 full-time employees at the time of application, with at least 51% of those employees either (i) currently residing in a Disproportionately Impacted Area or (ii) having been arrested for, convicted of, or adjudicated delinquent for any offense that is eligible for expungement under the Cannabis Regulation and Tax Act (the Adult Use Act) or a member of an impacted family.

Keeping these people employed during the pandemic is difficult or impossible for some applicants because the individuals must be full-time employees at the time the applications were submitted, which were due on or before April 30, 2020.

Due to the severe economic conditions resulting from the COVID-19 pandemic, these applicants can now submit an Attestation form to the DOA and will no longer be required (for now) to maintain all employees that help satisfy the social equity criterion throughout the duration of the application scoring period. Specifically, the DOA “has determined that due to the unprecedented economic conditions resulting from the COVID-19 pandemic, Applicants seeking to qualify as Social Equity Applicants under this criterion will not be required to maintain all employees that help satisfy this criterion throughout the duration of the application scoring period, so long as the Applicant executes the attached attestation.”

If the applicant is eventually awarded a license, the applicant will be required to, within 60 days of receiving the license, employ the required number of individuals with the required status to meet the statutory qualifications of a Social Equity Applicant.

If you plan to request relief of the requirement to maintain employment for qualifying individuals, the Attestation form must be submitted to AGR.ADULTUSE@Illinois.gov.

In the Weeds - The Fox Rothschild Cannabis Law Blog

In February 2020, the California Department of Food and Agriculture (“CDFA”) released its proposed regulations for a first of its kind appellation program for cannabis cultivators.  The appellation program was established through the same law that regulates California’s cannabis industry, the Medicinal and Adult-Use Cannabis Regulations and Safety Act (“MAUCRSA”); however, the CDFA had to establish its regulations to implement that program.

After releasing the proposed regulations in February 2020 there was a public comment period, which ended in May 2020.  Since then, there have been no statements from the CDFA on changes to the proposed regulations; however, it is highly likely that the general concepts of the regulations will remain after any revisions are made based on public comments.

Below are the key general concepts of the CDFA’s proposed appellation regulations:

  • Cannabis products can only be marketed as being produced or grown from a specific county or appellation of origin if 100% of the cannabis was produced from that county or appellation.
  • Licensed cannabis companies must file a notice with the CDFA prior to using an appellation of origin.
  • Licensees can submit a petition with the CDFA to establish appellations throughout the state. Those petitions must provide the following;
    • A general description and location of the proposed geographical area;
    • Evidence of use of the appellation name;
    • A description and documentation of the boundary of the proposed appellation of origin;
    • A description and evidence of distinctive geographical features affecting cannabis cultivation in the boundary;
    • Identification and definition of all standard, practice, and cultivar requirements of the proposed appellation of origin;
    • A description and evidence of the legacy, history, and economic importance of cannabis cultivation in the area; and
    • A list of cultivator license types issued by the department (such as Indoor, Mixed-light Tier 1, Mixed-light Tier 2, or Outdoor) which are prohibited from using the appellation of origin.
  • Once the petition is filed, the CDFA will issue a notice of the petition and there will be a 30-day public comment period. The CDFA will issue its determination on the petition after the public comment period.

The use and protections of cannabis appellations can help old school cultivators in California’s historic cannabis areas, such as Mendocino, Humboldt, and Trinity counties, and increase demand for products grown in those areas and in particular appellations.  By establishing appellations and setting standards to use such appellations, stakeholders can secure much needed marketing recognition because consumers will be able to rely on consistent products from each appellation.  Similar to wine, a protected cannabis appellation can provide consumers with product consistency and stakeholders with increased product value.

The highly anticipate North Carolina Farm Act, Senate bill 315, was recently signed by the Governor. However, all reference to updating the state’s industrial hemp program was removed from the final version, leaving the highlights of the bill to be marketing for sweetpotatoes (now one-word) and the broadened definition of agritourism.

Since 2019, ten versions of the bill have circulated the NC legislature in an effort to establish a more permanent NC hemp plan. The final 11-page Farm Bill scrapped 15 pages of hemp industry-related law, forcing the industry to wait a bit longer for a more permanent plan. The North Carolina Industrial Hemp Commission has noted in meetings over the last few months the lack of resources to transition its program, and the concern of uncertainty shared by all industry players as the current pilot program expires in October. The Commission may have known to not expect finality as it discussed a request to extend the current pilot program for two additional years.

It was better to eliminate the hemp provisions from the bill rather than pass them in their latest form. The proposed program sought to criminalize smokable hemp, increase licensing requirements for industrial farmers, and impose unnecessary bond requirements.  All these regulations would create massive hurdles for the budding industry. Ideally, more time will allow all parties to come to an agreement on a workable plan.

The global COVID-19, or coronavirus, pandemic has caused instability, uncertainty, and a downturn in most industries, and the cannabis industry has not been immune. The pandemic has caused several cannabis companies to terminate deals or modify contracts. However, the ability to terminate deals or modify contracts relies heavily on provisions within the applicable contracts. If a cannabis company is looking to modify a contract or terminate a deal they should begin by looking at the applicable contract and whether or not it contains a “Force Majeure” provision.

For further details on how Force Majeure may apply to your cannabis company’s situation, our firm has written the following articles/blogs on the issue:

 

In Illinois, 75 new adult use dispensary licenses were scheduled to be awarded on May 1, 2020. But, because of COVID-19, those licenses have been delayed by Governor Pritzker’s Executive Order 2020-34 for the duration of the Gubernatorial Disaster Proclamations or until the Illinois Department of Financial and Professional Regulation announces a new date.

Recently, the IDFPR offered relief to applicants that intended to qualify as a Social Equity Applicant by hiring a certain number of qualifying employees. One way to qualify as a Social Equity Applicant in Illinois is to hire a minimum of 10 full-time employees at the time of application, with at least 51% of those employees either (i) currently residing in a Disproportionately Impacted Area or (ii) having been arrested for, convicted of, or adjudicated delinquent for any offense that is eligible for expungement under the Cannabis Regulation and Tax Act or a member of an impacted family.

The licensing delay causes additional problems for these applicants because the individuals must be full-time employees and must have been full-time employees at the time the applications were submitted, which were due on or before January 2, 2020. Due to the severe economic conditions resulting from the COVID-19 pandemic, these applicants can now submit an Attestation form to the IDFPR and will no longer be required (for now) to maintain all employees that help satisfy the social equity criterion throughout the duration of the application scoring period. If the applicant does eventually receive a dispensary license, the applicant will be required to, within 60 days of receiving the license, employ the required number of individuals with the required status to meet the statutory qualifications of a Social Equity Applicant.

As COVID-19 continues to rapidly spread, individuals are seeking remedies to prevent or mitigate the effects of COVID-19. Some companies are claiming their CBD products can provide a variety of immunities from COVID-19. These unsubstantiated claims pose not only a threat to consumers who believe these claims but also to the credibility of other cannabis businesses and the cannabis industry as a whole.

State and federal government agencies keep a close eye on health-related claims made by companies that provide CBD products, specifically those relating to the potential health benefits of CBD. States with medical or recreational cannabis regulations generally contain provisions prohibiting advertising that contains any false or misleading information. Without scientific evidence substantiating the claims made, government agencies are reluctant to permit advertising that states there are health benefits to consuming CBD products.

On April 1, the Federal Trade Commission and the Food and Drug Administration sent a warning letter to the headquarters of Neuro XPF — a CBD products company — demanding the company cease the sale and advertising of products for the mitigation, prevention, treatment, diagnosis or cure of COVID-19. The FDA stated in its letter that such claims qualify the CBD products as “unapproved new drugs sold in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act)” and as “misbranded drugs under section 502 of the FD&C Act.” Neuro XPF had a page of its website titled “CRUSH CORONA,” which stated the best defense against COVID-19 starts with a strong immune system. The company wanted “everyone to take CBD and take advantage of its potential to help prepare your body to fight against a coronavirus infection.” Neuro XPF promptly removed the page from its website.

Attorney generals are dealing with this issue on the state level as well. For example, the Oregon Attorney General’s Office forced a Portland CBD store to take down advertising claiming its products could increase lung support immunity to fight COVID-19. While the store did not intend to mislead consumers with their advertising, the attorney general interpreted the sign as a claim that CBD provides an immunity from COVID-19. Similarly, New York Attorney General Letitia James ordered a CBD products company to cease and desist the marketing of its product, which the company claimed provided “Protection from Corona Virus with Immunity Oil.”

It is important during this time that cannabis businesses remain accountable and ensure they are following state and federal regulations regarding advertising. Without scientific evidence, cannabis businesses may not claim CBD provides any form of immunity or cure to COVID-19. Businesses should refrain from making any claims that suggest their CBD products may prevent or mitigate the effects of COVID-19.

SanitizerAs the country grapples with the COVID-19 pandemic and drastic changes to the business environment, some cannabis companies have decided to pitch in and use some of their manufacturing and processing capacity to produce hand sanitizer. In California, companies such as CannaCraft and The Galley have converted portions of their processing facilities to produce hand sanitizer. In Massachusetts, the Commonwealth Dispensary Association partnered with the Massachusetts Health & Hospital Association to produce sanitizer, and its members believe they may be able to produce as much as 5,000 gallons of sanitizer per week, if needed. North of the border, Canadian extractor and processor The Valens Company recently announced that it will begin production of hand sanitizer liquid and plans to donate 40,000 bottles to frontline health care workers.

Cannabis processors that use ethanol in their extraction processes can easily pivot to the production of hand sanitizer, as ethanol is one of the three key ingredients used in most hand sanitizers. However, any cannabis business that wishes to get involved in the production of hand sanitizer should consider some important issues.

First, in order to avoid any issues with the Food and Drug Administration, all hand sanitizer products should be prepared in accordance with the guidance recently released by the U.S. Department of Health and Human Services, titled “Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) – Guidance for Industry.” A copy of that policy can be found here. Per the policy, sanitizer may only be prepared using the specified list of approved ingredients and in accordance with the formula detailed in the policy, and any company that produces hand sanitizer must register with the FDA as an over-the-counter drug manufacturer.

The other issue for cannabis companies to consider is their insurance coverage, since the production of hand sanitizer could be considered a change in the company’s line of business. The first step is to review your current policy to see if it already covers other manufacturing activities. If not, the next step would be to contact your insurer to revise the policy. If hand sanitizer is produced in accordance with the HHS policy described above the insurance company may not have any issue, as it may view those activities as a lesser risk than cannabis processing. In that case the insurance premiums should, at worst, remain steady.

It’s great to see cannabis companies doing their part to alleviate shortages of hand sanitizer, and attorneys at Fox are ready to help protect those companies that choose to produce sanitizer to protect others.